Cardiovascular Disease: A Metabolic Disease, Not a Lipid Disease
The dominant clinical framework for cardiovascular disease (CVD) prevention (the lipid hypothesis) holds that elevated LDL cholesterol is the primary causal driver of atherosclerosis and cardiovascular events, and that reducing LDL-C through dietary fat restriction and statin therapy is the primary preventive strategy. This framework has shaped clinical practice for 50 years and continues to drive the majority of CVD prevention guidelines.
The evidence base for this framework, however, is significantly weaker than is commonly understood, and an alternative framework (the metabolic hypothesis of CVD) is better supported by the totality of the evidence. In the metabolic hypothesis, CVD is primarily a disease of insulin resistance, chronic hyperinsulinemia, and the atherogenic dyslipidemia that follows from them, rather than a disease of dietary saturated fat and elevated LDL-C.
The Limitations of the LDL-C Hypothesis
The LDL-C hypothesis rests on several pillars: the epidemiological association between LDL-C and CVD risk in population studies; the mechanistic plausibility of LDL-C deposition in arterial walls; and the clinical evidence that statin-mediated LDL-C reduction reduces cardiovascular events. Each of these pillars has significant limitations.
"Cardiovascular disease is not a disease of dietary fat, it is a disease of metabolic dysfunction. The atherogenic process begins with endothelial injury driven by oxidative stress, not by dietary saturated fat.
The epidemiological association between LDL-C and CVD is inconsistent across populations and age groups. In patients over 60 years of age, multiple studies have found an inverse association between LDL-C and total mortality. Lower LDL-C is associated with higher mortality. The PREDIMED trial, the Lyon Diet Heart Study, and multiple meta-analyses of dietary fat and CVD outcomes have failed to demonstrate that reducing dietary saturated fat reduces cardiovascular mortality.
The mechanistic argument (that LDL-C deposits in arterial walls and causes atherosclerosis) is complicated by the role of LDL particle size. Small dense LDL particles (sdLDL) are significantly more atherogenic than large buoyant LDL particles: they are more susceptible to oxidation, have a higher affinity for arterial proteoglycans, and are more readily taken up by macrophages to form foam cells. Two patients with identical LDL-C values may have dramatically different atherogenic risk depending on their LDL particle size distribution, which is determined primarily by insulin resistance and dietary carbohydrate intake, not by dietary saturated fat.
The Atherogenic Dyslipidemia of Insulin Resistance
The dyslipidemia most strongly associated with cardiovascular risk is not elevated LDL-C but the triad of elevated triglycerides, low HDL-C, and small dense LDL (the atherogenic dyslipidemia of insulin resistance). This pattern is driven by chronic hyperinsulinemia through the mechanisms described in Module 2: elevated insulin drives hepatic VLDL secretion (raising triglycerides), CETP-mediated lipid exchange produces sdLDL and triglyceride-enriched HDL, and hepatic lipase catabolizes the triglyceride-enriched HDL (lowering HDL-C).
This atherogenic dyslipidemia is directly and rapidly improved by dietary carbohydrate restriction. Multiple clinical trials have demonstrated that a low-carbohydrate diet reduces triglycerides by 30–50%, raises HDL-C by 10–20%, and shifts LDL particles from small dense to large buoyant (all within 4–8 weeks). These improvements are consistent with the metabolic hypothesis: reducing dietary carbohydrate reduces chronic hyperinsulinemia, which reduces hepatic VLDL secretion and the downstream dyslipidemia.
Endothelial Dysfunction: The Earliest Cardiovascular Lesion
Endothelial dysfunction (impaired endothelium-dependent vasodilation) is the earliest detectable cardiovascular lesion and precedes atherosclerosis by years to decades. It is driven by multiple mechanisms that are directly related to insulin resistance: oxidative stress from chronic hyperglycemia and hyperinsulinemia reduces endothelial nitric oxide synthase (eNOS) activity; elevated uric acid directly inhibits eNOS; advanced glycation end-products (AGEs) from chronic postprandial hyperglycemia cross-link collagen and impair arterial compliance; and the chronic low-grade inflammation of metabolic disease activates endothelial adhesion molecules that initiate the atherosclerotic process.
Endothelial function is measurable clinically by flow-mediated dilation (FMD) of the brachial artery, which is not routinely performed in clinical practice but is used as a research endpoint. More practically, the combination of elevated hsCRP, elevated uric acid, and the atherogenic dyslipidemia pattern provides a clinical picture of endothelial dysfunction that warrants aggressive dietary intervention.
The Role of Dietary Fat in Cardiovascular Disease
The evidence that dietary saturated fat causes cardiovascular disease is significantly weaker than is commonly taught. The Women's Health Initiative Dietary Modification Trial (Howard et al., 2006) (the largest randomized trial of a low-fat diet) enrolled 48,835 postmenopausal women and randomized them to a low-fat dietary intervention or control for 8.1 years. The intervention group achieved a significant reduction in dietary fat intake but showed no significant reduction in cardiovascular events, stroke, or total mortality.
The Sydney Diet Heart Study (Ramsden et al., 2013) and Minnesota Coronary Experiment (Ramsden et al., 2016) (both suppressed for decades and discussed in detail in Module 5) demonstrated that replacing saturated fat with linoleic acid-rich vegetable oils reduced LDL-C but increased cardiovascular and total mortality. These findings are consistent with the metabolic hypothesis: the cardiovascular harm of industrial seed oils is mediated not through LDL-C but through mitochondrial membrane damage, systemic inflammation, and the atherogenic effects of oxidized linoleic acid metabolites (OXLAMs).
The Clinical Prescription for CVD Prevention
The clinical prescription for CVD prevention from a metabolic perspective differs substantially from the standard lipid-centric approach. The primary targets are insulin resistance (addressed by carbohydrate restriction), atherogenic dyslipidemia (addressed by carbohydrate restriction and seed oil elimination), systemic inflammation (addressed by elimination of ultra-processed foods and seed oils, addition of omega-3 fatty acids), and endothelial dysfunction (addressed by the combination of the above plus uric acid reduction through fructose restriction).
Statin therapy remains appropriate for patients with established cardiovascular disease or very high cardiovascular risk, where the evidence for event reduction is robust. However, statin therapy as primary prevention in patients without established CVD (particularly in patients with the atherogenic dyslipidemia of insulin resistance) should be considered in the context of the full metabolic picture, not solely on the basis of LDL-C.